DNA microarray data integration by ortholog gene analysis reveals potential molecular mechanisms of estrogen-dependent growth of human uterine fibroids by Tao Wei et al.
BioMed CentralBMC Women's Health
ssOpen AcceResearch article
DNA microarray data integration by ortholog gene analysis reveals 
potential molecular mechanisms of estrogen-dependent growth of 
human uterine fibroids
Tao Wei1, Andrew G Geiser2, Hui-Rong Qian3, Chen Su1, Leah M Helvering2, 
Nalini H Kulkarini1, Jianyong Shou1, Mathias N'Cho1, Henry U Bryant2 and 
Jude E Onyia*1
Address: 1Integrative Biology, Lilly Research Laboratories, Greenfield, Indiana 46140, USA, 2Bone and Inflammation, Lilly Research Laboratories, 
Indianapolis, Indiana 46285, USA and 3Discovery Statistics, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Email: Tao Wei - weita@lilly.com; Andrew G Geiser - ageiser@lilly.com; Hui-Rong Qian - qianhu@lilly.com; Chen Su - chen_su@lilly.com; 
Leah M Helvering - l.helvering@lilly.com; Nalini H Kulkarini - kulkarninh@lilly.com; Jianyong Shou - shou@lilly.com; 
Mathias N'Cho - n_mathias@lilly.com; Henry U Bryant - hub30@lilly.com; Jude E Onyia* - jeo@lilly.com
* Corresponding author    
Abstract
Background: Uterine fibroids or leiomyoma are a common benign smooth muscle tumor. The tumor growth is well
known to be estrogen-dependent. However, the molecular mechanisms of its estrogen-dependency is not well
understood.
Methods: Differentially expressed genes in human uterine fibroids were either retrieved from published papers or from
our own statistical analysis of downloaded array data. Probes for the same genes on different Affymetrix chips were
mapped based on probe comparison information provided by Affymetrix. Genes identified by two or three array studies
were submitted for ortholog analysis. Human and rat ortholog genes were identified by using ortholog gene databases,
HomoloGene and TOGA and were confirmed by synteny analysis with MultiContigView tool in the Ensembl genome
browser.
Results: By integrated analysis of three recently published DNA microarray studies with human tissue, thirty-eight genes
were found to be differentially expressed in the same direction in fibroid compared to adjacent uterine myometrium by
at least two research groups. Among these genes, twelve with rat orthologs were identified as estrogen-regulated from
our array study investigating uterine expression in ovariectomized rats treated with estrogen. Functional and pathway
analyses of the twelve genes suggested multiple molecular mechanisms for estrogen-dependent cell survival and tumor
growth. Firstly, estrogen increased expression of the anti-apoptotic PCP4 gene and suppressed the expression of growth
inhibitory receptors PTGER3 and TGFBR2. Secondly, estrogen may antagonize PPARγ signaling, thought to inhibit fibroid
growth and survival, at two points in the PPAR pathway: 1) through increased ANXA1 gene expression which can inhibit
phospholipase A2 activity and in turn decrease arachidonic acid synthesis, and 2) by decreasing L-PGDS expression which
would reduce synthesis of PGJ2, an endogenous ligand for PPARγ. Lastly, estrogen affects retinoic acid (RA) synthesis
and mobilization by regulating expression of CRABP2 and ALDH1A1. RA has been shown to play a significant role in the
development of uterine fibroids in an animal model.
Conclusion: Integrated analysis of multiple array datasets revealed twelve human and rat ortholog genes that were
differentially expressed in human uterine fibroids and transcriptionally responsive to estrogen in the rat uterus.
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BMC Women's Health 2007, 7:5 http://www.biomedcentral.com/1472-6874/7/5Functional and pathway analysis of these genes suggest multiple potential molecular mechanisms for the poorly
understood estrogen-dependent growth of uterine fibroids. Fully understanding the exact molecular interactions among
these gene products requires further study to validate their roles in uterine fibroids. This work provides new avenues of
study which could influence the future direction of therapeutic intervention for the disease.
Background
Leiomyoma or uterine fibroids are the most common
benign tumor, occurring in approximately 60% of women
during their lifetime[1]. In spite of its generally benign
nature, uterine fibroids cause an array of substantial
health problems in some women such as pressure or pain,
excessive uterine bleeding and problems related to preg-
nancy [2]. As a consequence, uterine fibroids account for
approximately one-third of all hysterectomies in the
United States or about 200,000 hysterectomies per year
[3]
Although the etiology of the disease is largely unknown, it
is clear that growth of uterine fibroids depends on the
ovarian hormones estrogen and progesterone [2]. This
hormonal dependency is supported by the following
observations. Uterine fibroids are observed only after
menarche, increase in size during pregnancy, and fre-
quently regress after menopause (reviewed in [2]). The
tumors can be induced to regress by surgical ovariectomy
or by treatment with GnRH agonists which induce a
hypoestrogenic state[4]. Tissue estrogen concentrations
are elevated in uterine fibroids compared to myometrium,
which may result from increased aromatase activity [5].
Estrogen produces diverse biological effects mediated by
estrogen receptors (ER). When bound to estrogen, the ER
modulates the transcriptional activity of target genes [6,7].
Evidence shows that one effect of estrogen is to increase
the levels of both estrogen receptor (ER) and progesterone
receptor (PR) [2]. It has been recently demonstrated that
estrogen can stabilize ER mRNA, increasing the level of
cellular ER protein [8].
While it is well established that growth of uterine fibroids
depends on estrogen, molecular mechanisms of such
estrogen dependency are largely unknown. Numerous
studies have indicated that estrogen may mediate fibroid
growth through the mitogenic effects of growth factors
such as transforming growth factor-β and basic fibroblast
growth factor (reviewed in [2]). There have been a few
recent studies addressing molecular mechanisms of func-
tional interaction between estrogen signaling and growth
factor-mediated signaling in the pathogenesis of uterine
fibroids. Work by Hayashi et al [9] in estrogen-dependent
cancers provides an example where the constitutively acti-
vated MAPK signaling pathway in endometrial cancer
cells might enhance the transcriptional activity of ERα via
phosphorylation of its AF-1 domain. Wnt signaling was
recently implicated in the pathogenesis of uterine fibroids
where the secreted frizzled related protein 1 (sFRP1)
mRNA [10] was found to be significantly elevated in the
tumor, and regulated by estrogen treatment. It was shown
that sFRP1 contributes to fibroid growth through an anti-
apoptotic effect.
A recent report has shown that PPARγ activation by its lig-
and (i.e., prostaglandin J2) in uterine fibroids is growth
inhibitory and mediated at least in part by negative cross-
talk between ER and PPARγ signaling pathways [11].
However, the exact molecular mechanisms of how such
interaction occurs between the two nuclear receptor sign-
aling pathways remain to be answered. Elevated levels of
PPARγ, retinoid × receptor alpha (RXRα), and all-trans
retinoic acid were observed in human uterine fibroids,
and retinoids in combination with estrogen was shown to
induce development of uterine fibroids in a guinea pig
model [12].
DNA microarray technology allows simultaneous interro-
gation of tens of thousands of genes [13]. Several studies
have applied the technology to identify genes that were
differentially expressed in human uterine fibroids com-
pared to adjacent normal myometrium [14]. The technol-
ogy has also been applied to identify estrogen-regulated
genes in the adult rat uterus [15]. To understand the
molecular interactions involved in estrogenic support of
uterine fibroid growth, we integrated results from the
above DNA microarray studies using ortholog analysis.
Orthologous genes are related by direct evolutionary
descent and should play similar developmental or physi-
ological roles [16]. This study identified twelve human
and rat orthologous genes that were differentially
expressed in human uterine fibroids and estrogen-regu-
lated in the adult rat uterus, and describes their possible
cellular and physiological roles in estrogen-dependent
tumor growth.
Methods
Published DNA microarray data sets
Table 1 lists four published DNA microarray data sets
used in this work. Briefly, researchers [14,17,18] profiled
biopsy samples taken from uterine fibroids and myome-
trial tissues of each patient (paired experimental design)
to identify differentially expressed statistically significant
(P < 0.05) genes. Helvering et al [15] profiled genes
expressed in the uteri of adult ovariectomized rats treatedPage 2 of 12
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ulated genes were identified as genes with false discovery
error rates < 0.05 [19] and showed an opposite direction
of change when comparing genes differentially expressed
between ovariectomized and sham controls versus genes
differentially expressed between ovariectomized controls
with ovariectomized animals treated with estrogen (E) at
either time points
Identification of human and rat ortholog genes that are 
estrogen responsive and differentially expressed in uterine 
fibroids
Figure 1 shows the procedure that was employed to iden-
tify human and rat ortholog genes that were differentially
expressed in human uterine fibroids and estrogen-regu-
lated in rat uterus. In the first step two gene lists were con-
structed. The first gene list included human genes
differentially expressed in human uterine fibroids identi-
fied by three independent groups [14], which were
retrieved from either published papers or from the Gene
Expression Omnibus database [20]. Since the three stud-
ies employed distinct Affymetrix chip types the informa-
tion of chip comparison was retrieved from the NetAffx
web site[21] to map genes from one chip type to another.
Genes commonly identified by two or three groups were
regarded as true differentially expressed genes and thus
selected for ortholog analysis. The second gene list
included estrogen-responsive genes in the rat uterus
which were obtained from the work by Helvering et
al[15]. The second step was to identify putative ortholog
genes from these two gene lists. Two major eukaryotic
ortholog gene databases, namely HomoloGene [22] and
TOGA [23], were queried for each of the tumor differen-
tially expressed genes to identify putative rat orthologs
and LocusLink numbers were then used to retrieve
Affymetrix probe sets on rat RG-U34A chips. These probe
sets were next compared with probe sets identified by
Helvering et al [15] to find putative human rat orthologs.
Finally, an in silico confirmation of expression and
ortholog gene identity was performed by examining each
Affymetrix probe set for its specificity to measure expres-
sion using the BLAT program [24] which aligned Affyme-
trix's target sequences against both human and rat
genomes. Genes were considered if their Affymetrix target
sequences mapped to only one major genome location.
To confirm orthologous genes identified above, each gene
was queried in the Ensembl genome browser [25] and
gene structure, chromosomal location and synteny infor-
mation were visually examined with Ensembl MultiCon-
tigView [25]. Lastly, functional and pathway analysis of
ortholog genes were conducted to understand cellular and
physiological implications.
To calculate functional distribution of the human genes
differentially expressed in uterine fibroids, a web tool
FatiGO developed by [26] was used according to its on-
line instruction.
Results
Genes differentially expressed in human uterine fibroids
Differential expression of genes between human uterine
fibroids and adjacent normal myometrium were identi-
fied by three independent research groups as shown in
Table 1. The number of genes identified was significantly
different among the three studies. All three studies used
matched fibroid and myometrial tissue. However, the
studies differed in the following aspects. First, the ethnic
background of the patients was very different. For exam-
ple, in Wang's experiment the patients were largely Afri-
can-American whereas in the Tsibris et al study the
patients were mainly of Northern European descent. It is
well known that uterine fibroids are much more prevalent
in African-American women than in Caucasian women
(reviewed in [2]). Secondly, tissues were sampled from
patients at different ovarian phases. The number of genes
identified was significantly greater in the Hoffman and
Tsibris studies where samples were taken from both the
follicular and luteal phases compared to the Wang study
where the authors sampled tissues from the follicular
phase only. Thirdly, different DNA chips were used (Table
1). These differed in the number of genes arrayed on each
chip, probe pairs for a given probe set, and probe pairs for
the same gene that might be taken from different metrix
target sequences. By using information on chip compari-
sons provided by NetAffx[21], we identified thirty-eight
genes (Table 2) that were commonly reported to be signif-
icantly changed in the same direction in two or three stud-
ies. Functional distribution within gene ontology space
Table 1: Published DNA microarray experiments
Species Tissue Chip Used Sample Size No of Genes Identified References
Human Uterine fibroids and normal myometrium HG-U95A HuGeneFL 9 pairs 106a [14]
HuGeneFL 7 pairs 68 [17]
HG-U133A 5 pairs 226b [18]
Rat Uteri from vehicle and estrogen treated animals RG-U34A 5 rats per treatment, 2 chip for each animal 3927c [15]
a the authors reported 145 genes but only 106 accessions could be retrieved from the paper.
b represents the number of the Affymetrix probe sets.
c the probe sets were significant with false discovery rate < 0.05 by either one – day or five – week estrogen treatment of ovariectomized rats.Page 3 of 12
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top ranked functional categories include transcription,
regulation of nucleotide metabolism, cell surface recep-
tor-linked signal transduction, protein metabolism, cell
organization and biogenesis, cell proliferation, intracellu-
lar signaling cascade, defense response and transport.
Estrogen-regulated genes in the uterus of ovariectomized 
adult rats
Helvering et al [15] evaluated short and long-term effects
of ovariectomy and treatment with estrogen on expression
changes in the uterus of ovariectomized rats. They found
that ovariectomy induced dramatic gene expression
changes in the uterus both at 13 days and at 5 weeks post
surgery with 1930 or 2908 Affymetrix probes changed,
respectively. Treatment of ovariectomized rats with 0.1
mg/kg/day 17-β ethinyl estradiol also induced significant
changes with 2389 probes altered following 1-day of treat-
ment and 2990 probes following 5-week treatment. In
total, there were 3927 Affymetrix probe sets that were
changed by ovariectomy and then altered in the opposite
direction by estrogen treatment of ovariectomized rats at
two time points.
Identification of orthologous genes differentially expressed 
in human uterine fibroids and regulated by estrogen in the 
rat uterus
Each of the thirty-eight genes differentially expressed in
human uterine fibroids was queried against the Homolo-
Gene and TOGA databases for rat ortholog genes, among
which twelve genes were found to be responsive to estro-
gen treatment in the rat uterus. Table 3 shows relative
changes of expression of the twelve human and rat
orthologs obtained from the original study. All twelve
genes showed high and consistent transcriptional changes
in uterine fibroids across two or three independent studies
and also responded to ovariectomy and estrogen treat-
ment in reversed manner consistently at both time points.
To confirm that the Affymetrix probe sets were indeed spe-
cific for each gene we confirmed their alignment with the
human and rat genomes using the BLAT tool [24] at UCSC
[27]. Except for Affymetrix target sequence of rat gene C1S
which produced two major alignments in the q42 cyto-
band of rat chromosome 4, one spanning 160981068 to
160993069 with 98.6% identities and the other spanning
160609849 to 160612122 with 75.7% identities, Affyme-
trix target sequences of all the other twelve genes gener-
ated one major alignment to the expected gene in the
human and rat genomes. For example, the rat target
sequence for the rat L-PGDS gene had a single, major
alignment with the L-PGDS gene on chromosome 3 in the
rat genome and the human target sequence generated a
single alignment with L-PGDS gene on chromosome 9 in
the human genome. Thus we believe that expression sig-
nals of the twelve human and rat orthologs, except for the
gene C1S, obtained by Affymetrix chips used in these stud-
ies could accurately measure mRNA abundance of the
twelve genes in the human and rat samples.
To demonstrate that the twelve genes are genuinely
human and rat ortholog genes, each of them was queried
in the UCSF and Ensembl genome browsers to visually
examine the local genome structure and compare them
between the two species. Figure 3 shows the genome struc-
ture of ALDH1A1 and ANXA1 as an example. Interest-
ingly, ALDH1A1 and ANXA1 genes map to a common
chromosomal region in both species and the genomic
structures are well conserved among human, mouse and
rat. This relationship, regarded as a synteny, provides
strong evidence for orthologship of the two genes among
human, rat and mouse. Similarly, the rest of the ten genes
Diagram of DNA microarray data integration by ortholog gene nalysisFigure 1
Diagram of DNA microarray data integration by ortholog 
gene analysis.Page 4 of 12
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regions in two species (data not shown).
A literature search was conducted for each of the twelve
genes to determine if others have previously identified
these genes to be directly regulated by estrogen (Table 3).
Cellular retinoic acid binding protein 2 (CRABP2) and
aldehyde dehydrogenase 1 A1 (ALDH1A1) were previ-
ously shown to directly respond to estrogen in the rat
uterus [28,29] in the same fashion as observed by Helver-
ing using DNA microarray. Lipocalin-type prostaglandin
D synthase (L-PGDS) was reported to respond to estrogen
in a more complicated fashion depending on the tissues/
organs. For example, L-PGDS transcription was induced
in the medial basal hypothalamus and repressed in the
preoptic area in female adult mice by estrogen [30,31].
Transcription of L-PGDS was also induced in mouse heart
in vivo specifically by estrogen receptor beta via a func-
tional estrogen-responsive element in the L-PGDS pro-
moter [32]. Castro-Caldas et al [33] demonstrated that
estrogen induced de novo expression of annexin A1
(ANXA1) and stimulated its secretion in the human
CCRF-CEM acute lymphoblastic leukemia cell line appar-
ently via a mechanism independent of the intracellular
estrogen receptor. Consistent with this result we couldn't
find any putative estrogen responsive element in its 5 kb
promoter sequence. Expression of calcitonin receptor-like
receptor (CALCRL) was inhibited by estrogen in the rat
uterus [34] and placenta [35]. Nuclear receptor subfamily
4, group A, member 1 (NR4A1) whose human promoter
Functional distribution of thirty-eight genes differentially expressed in human uterine fibroidsigure 2
Functional distribution of thirty-eight genes differentially expressed in human uterine fibroids. The analysis was done using a 
web tool FatiGO developed by Al-Shahrour et al. [26]. Since some genes are involved in multiple biological processes the sum 
of percentage is more than 100.Page 5 of 12
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[36], was reported [37] to be an early responsive gene in
the ovarectomized rat uterus to estrogen treatment. Insu-
lin-like growth factor II (IGF2) was regulated in the estro-
gen-treated rat uterus (Table 3), but had previously been
reported to be estrogen non-responsive. Rather, IGF-1 was
found to be regulated by estrogen in human uterine
fibroids [38], rhesus monkey myometrium [39] and rat
uterus [40].
In summary, by integrating multiple independent DNA
microarray studies of differentially expressed genes in
human uterine fibroids a group of thirty-eight genes were
identified as consistently changed in the tumor versus sur-
rounding normal myometrium. By ortholog gene analysis
we identified a subset of these genes that were estrogen-
regulated in the rat array study. Six of the twelve ortholog
genes have previously been described to be regulated by
estrogen while the remaining genes have yet to be inde-
pendently verified as estrogen-responsive.
Discussion
DNA microarray technology provides us with a great
opportunity for looking at molecular mechanisms of dis-
ease development on a whole genome scale. While a few
public databases have been built to facilitate data sharing
Table 2: Genes with differential expression in human uterine fibroids identified by two or three groups of researchers.
Accessiona Symbolb Gene Descritpionb Hc Tc Wc
NM_007168 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 -2.5 -5.7
NM_006720 ABLIM1 actin binding LIM protein 1 -3.3 -4.28
NM_000689 ALDH1A1 aldehyde dehydrogenase 1 family, member A1 -3.5 -7.98 -4
NM_000700 ANXA1 annexin A1 -4.1 -4.32
NM_001674 ATF3 activating transcription factor 3 -8.8 -6.04
M18767 C1S complement component 1, s subcomponent -2.5 -3.2
NM_004772 C5orf13 chromosome 5 open reading frame 13 2.45 2.81
NM_001218 CA12 carbonic anhydrase XII 3.81 4.8
U17473 CALCRL calcitonin receptor-like receptor -2.1 -1.7
NM_001870 CPA3 carboxypeptidase A3 (mast cell) -2.1 -8.18
NM_001878 CRABP2 cellular retinoic acid binding protein 2 3.05 5.12 2.6
AF003114 CYR61 cysteine-rich, angiogenic inducer, 61 -5.8 -5.3
AI826799 EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 -4.1 -4.51 -5
BC004490 FOS v-fos FBJ murine osteosarcoma viral oncogene homolog -9.5 -8.17
NM_007003 GAGEC1 G antigen, family C, 1 2.98 40.7
NM_000826 GRIA2 glutamate receptor, ionotropic, AMPA 2 7.48 38.8 4.9
J03242 IGF2 insulin-like growth factor 2 (somatomedin A) 16.8 2.6
NM_002178 IGFBP6 insulin-like growth factor binding protein 6 -4.5 -5.26
NM_004522 KIF5C kinesin family member 5C 2.12 9.02
AL021977 MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) -6.8 -3.38
NM_005923 MAP3K5 mitogen-activated protein kinase kinase kinase 5 -2.1 -4.13 -3
NM_002402 MEST mesoderm specific transcript homolog (mouse) 3.87 11.6 2.4
NM_002135 NR4A1 nuclear receptor subfamily 4, group A, member 1 -3.7 -3.78
NM_006198 PCP4 Purkinje cell protein 4 4.85 8.23
AI934473 PIK3R1 phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) 3.01 2.21
BC002665 PLP1 proteolipid protein 1 (Pelizaeus-Merzbacher disease, spastic paraplegia 2, uncomplicated) 4.75 12.1
BC005939 PTGDS prostaglandin D2 synthase 21kDa (brain) -2 -3.47 -2
D86096 PTGER3 prostaglandin E receptor 3 (subtype EP3) -4.2 -2.8
NM_002937 RNASE4 ribonuclease, RNase A family, 4 -2 -3.38
U89281 RODH 3-hydroxysteroid epimerase 1.93 3.34
NM_000602 SERPINE1 serine (or cysteine) proteinase inhibitor, clade E, member 1 -4.4 -4.09
BG528420 SOX4 SRY (sex determining region Y)-box 4 3.98 2.81
NM_003242 TGFBR2 transforming growth factor, beta receptor II -1.8 -2.02
NM_021992 TMSNB thymosin, beta, identified in neuroblastoma cells 1.59 5.51
NM_007116 TNXB tenascin XB -2.2 -6.28
NM_003294 TPSB2 tryptase beta 2 -4.1 -24.3
AF349719 TRO trophinin 1.74 3.3
NM_001071 TYMS thymidylate synthetase 2.1 9.12 3.3
a Genbank or RefSeq accession number.
b Gene symbol or description were obtained from the BioConductor Project.
c Fold change of gene expression in uterine fibroids vs myometrium. H, T and W represent studies by Hoffman et al. [18], Tsibris et al. [14] and 
Wang et al. [17] respectively.Page 6 of 12
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the data, particularly data generated from different organ-
isms, in order to generate testable hypotheses. In the
present work we integrated multiple microarray data sets
generated by independent research groups from two dif-
ferent species using ortholog gene analysis to try to dis-
cover molecular clues to estrogen-dependent growth of
human uterine fibroids. While this in silico analysis sug-
gests pathways and individual gene product involvement
in the regulation of fibroid tumor growth by estrogenic
signaling, the authors recognize the need for experimental
follow-up to prove these associations.
Thirty-eight human genes (Table 2) were identified in
common from three independent studies showing differ-
ential expression between uterine fibroids and normal
myometrium. Of these, twelve human and rat ortholo-
gous genes (Table 3) were shown to be estrogen-regulated
in the rat uterus. Since they are human and rat orthologs,
we inferred that they should share similar expression reg-
ulation and biological functions in both species. These
genes provide important clues to understand estrogen-
dependent growth of human uterine fibroids.
Prostaglandin E2 receptor subtype 3 (PTGER3 or EP3) is a
G-protein-coupled receptor activated by prostaglandin E2
that was down regulated in uterine fibroids. Alternative
splicing generates three isoforms: EP3 alpha, EP3 beta and
EP3 gamma, which differ in the putative cytoplasmic car-
boxy-terminal tail. It was demonstrated that while EP3
gamma is coupled to both stimulation and inhibition of
adenylate cyclase, EP3 alpha and beta are exclusively cou-
pled to inhibition of adenylate cyclase [43]. Shoji et al.
[44] demonstrated that EP3 plays an important role in
suppression of cell growth and its down-regulation
enhances colon carcinogenesis at a later stage. Transform-
Table 3: Human and rat orthologous genes differentially expressed in human uterine fibroids and E2-responsive in the rat uterus.
Gene Symbol Uterine fibroids 1-Day 5-Week Previous reports on E2 regulation
Ha Ta Wa ovx E2 ovx E2
prostaglandin E receptor 3 (subtype EP3) PTGER3 -4.2 -2.8 1.8 -1.8 1.6 -1.7 None
transforming growth factor, beta receptor II (70/80kDa) TGFBR2 -1.8 -2.0 3.3 -3.2 5.4 -15.6 None
Purkinje cell protein 4 PCP4 4.9 8.2 NS NS -1.4 2.4 None
calcitonin receptor-like receptor CALCRL -2.1 -1.7 1.9 -1.7 1.2 -1.3 [35] [34]
aldehyde dehydrogenase 1 family, member A1 ALDH1A1 -3.5 -8.0 -3.8 7.7 -9.0 4.5 -4.4 [28] [29]
annexin A1 ANXA1 -4.1 -4.3 -1.4 1.6 NS NS [33]
cellular retinoic acid binding protein 2 CRABP2 3.1 5.1 2.6 -23.1 37.6 NS NS [28] [29]
prostaglandin D2 synthase 21kDa (brain) L-PTGDS -2.0 -3.5 -2.1 2.0 -2.3 1.8 -2.0 [30, 31] [32]
nuclear receptor subfamily 4, group A, member 1 NR4A1 -3.7 -3.8 NS NS -1.8 5.4 [37] [64]
proteolipid protein 1 PLP1 4.8 12.1 1.3 -1.5 1.3 -1.3 None
ribonuclease, RNase A family, 4 RNASE4 -2.0 -3.4 NS NS 3.5 -4.3 None
insulin-like growth factor 2 (somatomedin A) IGF2 16.8 2.6 NS NS 2.2 -1.6 Contradictory to [38] [40] [39]
a Abbreviations: H for Hoffman et al study [18], T for Tsibris [14], and W for Wang et al. [17], ovx = ovariectomized rats, E2 = 17β – estradiol, and 
NS = not statistically significant at α = 0.05.
Conserved genomic structure of ALDH1A1 and ANXA1 genes among rat, mouse and humanFigure 3
Conserved genomic structure of ALDH1A1 and ANXA1 genes among rat, mouse and human. Both genes are located on the 
same chromosome with head-to-head configuration. The configuration is conserved among three organisms. Filled arrows indi-
cate transcription direction. Filled black bars are target sequences from which Affymetrix probes were derived. Over 200 kb of 
intergenic sequence is indicated by an empty arrow.Page 7 of 12
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normal epithelial cell proliferation and is increasingly
implicated in fibroid growth. Many tumor cell lines do
not respond to the inhibitory effects of TGF-β due to a
reduction or absence of the type II receptor (TGF-β R2)
[45]. The down-regulation of TGF-β R2 in uterine fibroids
is consistent with this finding. The PCP4 gene encoding
PEP-19 is a calmodulin-regulatory protein found abun-
dantly within neurons that was found to be increased in
uterine fibroids. A study in PC12 cells [46] demonstrated
that PEP-19 could inhibit apoptosis in the cells, suggest-
ing that its up-regulation in human uterine fibroids may
be similar. Thus, estrogen may promote cell survival and
tumor growth by increasing expression of the anti-apop-
totic PCP4 gene and by suppressing the expression of
growth inhibitory receptors PTGER3 and TGF-β R2.
The calcitonin receptor-like receptor (CALCRL or CRLR),
a G-protein coupled receptor, acts as a receptor for
adrenomedullin (ADM) or calcitonin gene related peptide
(CGRP) depending on which receptor activity modifying
protein (RAMP) it partners with [47]. Using a rat uterine
fibroid-derived cell line (ELT3), Thota and Yallampalli
[34] demonstrated that expression of CALCRL and
RAMP1 increased with progesterone and decreased with
estrogen, consistent with what Helvering et al found in the
array work (Table 3). Down-regulation of CALCRL expres-
sion in the tumor and in response to estrogen may impli-
cate two important aspects of the tumor growth, that is,
cell proliferation and angiogenesis.
L-PGDS has dual molecular functions. It catalyzes the
conversion of prostaglandin H2 (PGH2) to prostaglandin
D2 (PGD2) inside the cell and binds to small non-sub-
strate lipophilic molecules including retinal, retinoic acid
and thyroid hormone and serve as a transporter for these
molecules once secreted [48]. ANXA1 is a calcium-
dependent phospholipid binding protein and belongs to
the annexin family. It was originally identified as a protein
that apparently modulated the release of arachidonic acid
from cells [49]. Recent data have shown that ANXA1 may
specifically target cytosolic phospholipase A2 (PLA2) by
both direct enzyme inhibition and suppression of
cytokine-induced activation of the enzyme [50]. CRABP2
is a member of a large family of small proteins that specif-
ically bind lipophilic compounds such as fatty acids and
retinoids [28]. Recent work has suggested that CRABP2
may have a role in the movement of retinoic acid (RA) to
the RA receptors (RARs), thereby enhancing the action of
RA in the cells in which it is expressed. ALDH1A1 belongs
to the aldehyde dehydrogenase family and is a terminal
enzyme of the pathway catalyzing conversion of retinal to
RA [51]. NR4A1 (encoded by Nur77 in mouse, NGFI-B in
rat, and TR3 in human) is an immediate-early responsive
orphan nuclear receptor whose expression is rapidly
induced by a variety of extracellular stimuli including
estrogen as evidenced here (Table 3). Using Northern blot
RNA analysis Cicatiello et al [37] reported that NR4A1
was transiently activated in the uterus (up to 20-fold)
within 30–120 min after treatment of adult ovariect-
omized rats with estrogen.
Five of the ortholog genes (ANXA1, L-PGDS, ALDH1A1,
CRABP2 and NR4A1) were found to be linked via their
physiological functions following pathway analysis as
summarized in Fig. 4. Estrogen may antagonize PPARγ
mediated signaling first by up-regulating ANXA1 gene
expression, thereby inhibiting phospholipase A2 activity
and reducing arachinoic acid production, a common sub-
strate for prostaglandin synthesis. Secondly, estrogen may
antagonize PPARγ mediated signaling by down-regulating
L-PGDS gene expression, which reduces conversion of
PGH2 to PGD2 thus decreasing synthesis of PGJ2, an
endogenous ligand for PPARγ activation. Recent work
may provide clues to understand the physiological signif-
icance of these molecular events in the context of estro-
gen-dependent fibroid growth. Houston et al. [11]
demonstrated that PPARγ upon its activation by its endog-
enous ligand PGJ2, suppressed estrogen-dependent
fibroid growth. The authors hypothesized that PPARγ
achieved its antagonistic effect by competitively binding
to estrogen-responsive elements on promoters of genes
which may be required for estrogen-dependent tumor
growth. Yuan et al [52] showed that PPARγ activation by
pioglitazone greatly retarded the progression of rat
hepatic fibrosis. Shimada et al [53] reported that PPARγ
ligands, including PGJ2, induced apoptosis in colon can-
cer cells and the same group [54] demonstrated that
PPARγ plays an important role in the regulation of cell
growth and cell death in gastric epithelial cells. It was
reported [12] that human uterine fibroids expressed sig-
nificantly higher levels of PPARγ, retinoid × receptor α
and all-trans retinoic acid than myometrium. Thus we
hypothesize that estrogen helps tumor cell survival and
growth by interfering with PPARγ-mediated apoptosis at
multiple steps in the biosynthesis of its ligand.
Retinoic acid (RA) has been established as a biologically
active form of vitamin A (retinol). Fig 4 shows that bio-
synthesis of RA occurs by two sequential irreversible oxi-
dations, first producing retinal from retinol by retinal
dehydrogenases (RolDHs). The retinal is then oxidized to
RA by retinal dehydrogenases (RalDHs) of the alcohol
dehydrogenase (ADH) family 1 (also known as
ALDH1A1-3). Tsibris et al [12] demonstrated that estro-
gen induced formation of abdominal fibroids in the
guinea pig, and RA in combination with estrogen was
required to specifically induce formation of fibroids in the
uterus. Estrogen-induced guinea pig uterine fibroids are
similar to the human fibroids, in that they also expressedPage 8 of 12
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Multiple estrogen-regulated steps in the metabolisms of prostaglandin J2 and retinoic acid are implicated in estrogen-dependent growth of huma  uterine fibroidFigure 4
Multiple estrogen-regulated steps in the metabolisms of prostaglandin J2 and retinoic acid are implicated in estrogen-dependent 
growth of human uterine fibroids. Prostaglandin synthesis pathway was taken from the KEGG pathway database and simplified. 
Retinoic acid metabolic pathway was compiled based on previous work [51], [29]and [55]. E2 stands for 17 β-estradiol, PGH2 
for prostaglandin H2, PGD2 for prostaglandin D2, PGJ2 for prostaglandin J2, RA for retinoic acid, RAR for RA receptor, RXR 
for retinoid × receptor, PPAR for peroxisome proliferator-activated receptor. Five human and rat ortholog and estrogen-reg-
ulated genes (NR4A1, ANXA1, L-PGDS, ALDH1A1 and CRABP2) are in bold font. NR4A1 is nuclear receptor subfamily 4, 
group A, member 1, which is also called NGFI-B (neuronal growth factor-induced clone B) in rat, Nur77 in mouse and TR3 in 
human. Its roles in cell proliferation and apoptosis summarized in the figure were largely taken from Cao et al [36] and refer-
ences therein. ANXA1 stands for annexin A1, L-PGDS for lipocalin-type prostaglandin D2 synthase, ALDH1A1 and ALDH1A2 
for aldehyde dehydrogenase 1 family, member A1 and member A2 respectively, CRABP2 for cellular retinoic acid binding pro-
tein 2, COX1 and COX2 for cyclooxygenase 1 and 2, eRolDH for epithelial retinal dehydrogenase [63].
BMC Women's Health 2007, 7:5 http://www.biomedcentral.com/1472-6874/7/5increased levels of PPARγ, RXR-α and all-trans retinoic
acid. Our integrated analysis of expression data collected
by independent studies revealed that expression of two
genes, ALDH1A1 and CRABP2 for RA synthesis or mobili-
zation was differentially expressed in human uterine
fibroids and regulated by estrogen in the rat uterus. Previ-
ous studies in rodents have suggested that estrogen
directly induces uterine RA synthesis by increasing expres-
sion of epithelial retinal dehydrogenase (eRolDH) and
ALDH1A2 (reviewed in [29]). Reduction of ALDH1A1
expression (Table 3) may not directly result from estrogen
regulation but rather be due to feedback inhibition by RA
[55]. RA acts on tumor growth by binding and regulating
the tumor cell heterodimeric receptors RAR and RXR. RXR
may also exert its effects on tumor cell survival and growth
by partnering with PPARγ and/or NR4A1. NR4A1 was
originally recognized for its role in cell proliferation and
differentiation. It may confer its growth effects by trans-
activating target genes required for cell proliferation in
nucleus [56]. On the other hand, it also acts on mitochon-
dria (non-trans-activation activity) to induce apoptosis. It
was demonstrated that its nuclear export and initiation of
NR4A1-dependent apoptosis depends on the nuclear
exporting signal (NES) residing on its binding partner
RXR and is suppressed by RA [36]. Thus, increased expres-
sion of NR4A1 and elevated levels of RA in response to
estrogen could promote cell proliferation and suppress
pro-apoptosis activity. Proteolipid and DM20 encoded by
the PLP1 gene through alternative splicing are major
structural components of central nervous system myelin.
It has been well established that steroid hormones such as
estrogen and progesterone regulate the expression of mye-
lin proteins such as proteolipid protein (reviewed in
[57]). However, what roles PLP1 may play in the develop-
ment of human uterine fibroids needs further study. Sim-
ilarly we have little knowledge of what functions that
RNase A family, 4 (RNASE4) plays in the tumor growth. It
is worthwhile to note that directions of expression
changes of ANXA1, NR4A1 and PLP1 were opposite from
that of the estrogen treated rat uterus.
Human genetics studies have shown that 40–50% of
human uterine fibroids display karyotypically detectable
chromosomal abnormalities [2]. Twenty percent of the
abnormality is the characteristic translocation t(12:14)
[58,59]. The twelve estrogen-regulated genes identified in
the present study did not map to this translocation. The
most prominent predisposition genes involved in human
uterine fibroids, HGMI(c) and HMGI (Y), account for
nearly 50% of the genetic variation in human uterine
fibroids [59]. Dysregulation of these genes through chro-
mosomal translation is a major event in uterine fibroid
formation. Rearrangement of HMGI(C) and HMGI(Y) is
also a very frequent event in many mesenchymal tumors,
suggesting a critical role of the HMGI complex in tumori-
genesis. The two key estrogen regulated pathways (e.g. RA
and PPARγ) identified in the present study were both
reported to be interacting with the HMG complex. For
example, orchestrated action from PPARγ, HMGI(C), and
other transcription factors is required in directing adi-
pocyte differentiation [60]. Altered activity of these tran-
scription factors could lead to biased differentiation of
adipocytes or even adipocyte hyperplasia. Moreover, the
retinoic acid pathway could regulate or be regulated by
HMGI(C) during neuroblastoma tumorigenesis. Both
HMGI(C), and HMGI(Y) are expressed in neuroblastoma
cell lines and tumors and they are regulated by RA both at
the RNA and protein levels, and can affect the responsive-
ness of these cells to RA [61,62]. A causal link has been
proposed between HMGI(C) expression and RA induced
growth arrest during tumorigenesis. Given the pivotal
roles of the HMG complex in the fibroids and their inter-
action with PPARγ and RA pathways in controlling adi-
pocyte growth and tumorigenesis of neuroblastoma, we
speculate that estrogen may regulate fibroid growth
through the PPARγ and RA pathways and their interaction
with the HMGI(C) and HGMI(Y) complex. However, the
direct link between HMG complex with RA and/or PPARγ
in human uterine fibroids needs to be established experi-
mentally, and is an area for future investigation.
Conclusion
In conclusion, integration of multiple DNA microarray
studies through ortholog gene analysis identified twelve
uterine fibroid disease genes that may respond to estrogen
in the fibroid. Functional and pathway analyses suggested
multiple molecular mechanisms for estrogen-dependent
growth of human uterine fibroids: enhanced tumor cell
survival by increased expression of PCP4 and decreased
expression of TGF-β R2 and PTGER3 and the complex
interplay among five distinct nuclear receptors (ER, RAR,
RXR, NR4A1 and PPARγ) that may enhance tumor cell
survival and growth. Fully understanding the exact molec-
ular interactions among these genes requires further study
to validate their role in uterine fibroids. This work pro-
vides direction for studies which could influence the
future direction of therapeutic intervention for the dis-
ease.
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